Tenecteplase after clot removal for severe stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your legal representative must sign a consent form
- Before your stroke, you could live independently (able to do daily tasks alone)
- Your stroke must be from a blockage in one of the large arteries in your brain (internal carotid or middle cerebral)
- You had a clot-removal procedure (thrombectomy) that reopened the artery, and a brain scan shows a large zone of at-risk tissue
- You must meet specific brain scan criteria showing a mismatch between damaged and salvageable brain tissue
- You cannot have active bleeding, low platelets, uncontrolled high blood pressure, or other serious medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clot-busting drug called tenecteplase, given directly into the blocked artery, for people who have had a stroke caused by a medium-sized brain vessel blockage within the last 24 hours. It aims to see if this treatment is safe and effective in improving recovery.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
This trial tests whether giving a clot-busting drug (tenecteplase) before transferring you to a hospital that can do a procedure to remove the clot improves outcomes for people who had a stroke up to 24 hours earlier. You may qualify if you have a blockage in a large artery in the front of your brain and can still get the procedure.
This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.